Literature DB >> 20023685

The Framingham risk score is valuable in Europeans.

Luis M Ruilope.   

Abstract

Mesh：

Year:  2010        PMID： 20023685     DOI： 10.1038/nrneph.2009.205

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

Review 1.  Selected major risk factors and global and regional burden of disease.

Authors:  Majid Ezzati; Alan D Lopez; Anthony Rodgers; Stephen Vander Hoorn; Christopher J L Murray
Journal:  Lancet       Date:  2002-11-02       Impact factor: 79.321

Review 2.  Global burden of blood-pressure-related disease, 2001.

Authors:  Carlene M M Lawes; Stephen Vander Hoorn; Anthony Rodgers
Journal:  Lancet       Date:  2008-05-03       Impact factor: 79.321

3.  Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study.

Authors:  R S Vasan; M G Larson; E P Leip; W B Kannel; D Levy
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

4.  Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension.

Authors:  J He; P K Whelton; L J Appel; J Charleston; M J Klag
Journal:  Hypertension       Date:  2000-02       Impact factor: 10.190

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

Review 7.  The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.

Authors:  Luis Ruilope; Sverre E Kjeldsen; Alejandro de la Sierra; Giuseppe Mancia; Piero Ruggenenti; George S Stergiou; George L Bakris; Thomas D Giles
Journal:  Blood Press       Date:  2007       Impact factor: 2.835

8.  A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study.

Authors:  Nisha I Parikh; Michael J Pencina; Thomas J Wang; Emelia J Benjamin; Katherine J Lanier; Daniel Levy; Ralph B D'Agostino; William B Kannel; Ramachandran S Vasan
Journal:  Ann Intern Med       Date:  2008-01-15       Impact factor: 25.391

9.  Validating the Framingham Hypertension Risk Score: results from the Whitehall II study.

Authors:  Mika Kivimäki; G David Batty; Archana Singh-Manoux; Jane E Ferrie; Adam G Tabak; Markus Jokela; Michael G Marmot; George Davey Smith; Martin J Shipley
Journal:  Hypertension       Date:  2009-07-13       Impact factor: 10.190
  9 in total
  3 in total

1.  The role of radionuclide myocardial perfusion imaging for asymptomatic individuals.

Authors:  Robert C Hendel; Brian G Abbott; Timothy M Bateman; Ron Blankstein; Dennis A Calnon; Jeffrey A Leppo; Jamshid Maddahi; Matthew M Schumaecker; Leslee J Shaw; R Parker Ward; David G Wolinsky
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

2.  Cardiac risk assessment by gated single-photon emission computed tomography in asymptomatic end-stage renal disease patients at the start of dialysis.

Authors:  Jwa-Kyung Kim; Sung Gyun Kim; Hyung Jik Kim; Young Rim Song
Journal:  J Nucl Cardiol       Date:  2011-12-28       Impact factor: 5.952

3.  Cigarette smoking exacerbates the adverse effects of age and metabolic syndrome on subclinical atherosclerosis: the Bogalusa Heart Study.

Authors:  Shengxu Li; Miaoying Yun; Camilo Fernandez; Jihua Xu; Sathanur R Srinivasan; Wei Chen; Gerald S Berenson
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.